AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Phase ten therapy11/19/2023 ![]() ~ Investor conference call and webcast today at 8:30 a.m. ![]() cohort and 12-month follow up in the high-dose U.S. ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ![]() ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~
0 Comments
Read More
Leave a Reply. |